Lantheus Holdings Inc Stock News

Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Brian A. Markison - CEO & Director Mark Richard Kinarney - Vice President of Investor Relations Paul M.

Lantheus (LNTH) Q2 Revenue Falls 4%

Lantheus remains a highly profitable company with a dominant market share, an exceptionally strong balance sheet with nearly $1 billion in cash, and robust free cash flow. The stock's decline was driven by a slowdown in growth for key products, a surprise business divestiture, a pipeline failure, and a lowered full-year 2025 guidance. Management is actively repositioning the company away from l...

Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resilience PDUFA date set for March 6, 2026

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Man...

Lantheus remains fundamentally strong despite recent stock drops, with long-term prospects intact for PYLARIFY and Alzheimer's diagnostics. PYLARIFY dominates revenue and has a significant growth runway if adoption expands, representing a multi-billion dollar opportunity by 2030. Alzheimer's market entry is a bullish catalyst, with two promising imaging agents and a large, untapped addressable ...

Lantheus Holdings offers a compelling bull case with PYLARIFY and DEFINITY driving valuation and strong growth prospects. A headline multiple of 12x 2025 earnings obscures real risks around PYLARIFY revenue, pricing, and rising competition. PYLARIFY's dominance in prostate cancer imaging has fueled massive stock gains, but new competitors like Telix and Blue Earth threaten its market share.

BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nucl...